Perioperative / BP / CVS / Background Novo Nordisk Inc. / Novo Nordisk Inc. / /
Country
United States / /
Event
FDA Phase / Product Issues / /
IndustryTerm
serum-free media / container closure systems / carrier protein / similar products / treatment site / manufacturing / marketed products / /
MedicalCondition
local irritation / Hemophilia A / joint bleeding model hemophilia A / severe hemophilia / Carcinogenesis / hemophilia A. The / injury / hemophilia A. Deletion / hypersensitivity / hemophilic synovitis / hemophilia / dissociation / /
Organization
office of Blood Research / United States Food and Drug Administration Center for Biologics Evaluation and Research Pharmacology / FDA / Division of Hematology / Department of Health and Human Services / /
Person
Nissa A. Brown / Anne M. Pilaro / Maximum / Comment / Basil Golding / /
Position
Doses General / Pharmacologist / treating physician / producer / Non-clinical Pharmacology/Toxicology General / Director Division / Supervisory Toxicologist / /
Pharmacology Toxicology Memo, May 31, [removed]Novoeight